Media Releases | InSphero
Nov 06, 2019

InSphero joins Science Exchange Network to Offer Expanded Online Access to 3D InSight™ Microtissue Technology and Services

New R&D services platform will make it easier for researchers throughout the world to purchase InSphero assay ready models and services for drug efficacy and safety testing

Read More
 
 
Nov 01, 2019

InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

InSphero received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing, China. At the event, InSphero highlighted its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a breakthrough 3D cell technology for drug discovery and safety testing.

Read More
 
 
Oct 03, 2019

Akero Therapeutics and InSphero partner to evaluate AKR-001 using InSphero’s 3D InSight™ Human Liver Disease platform

3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH.

Read More
 
 
Sep 24, 2019

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery

New platform to combine stem cell and CRISPR gene-editing technology with proven 3D cell culture techniques for producing standardized pancreatic islet disease models

Read More
 
 
Aug 27, 2019

InSphero human liver disease platform selected to test Cyclerion’s sGC stimulator technology as potential therapeutic approach for NASH and fibrosis

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at Cyclerion Therapeutics, a clinical stage biopharmaceutical company, used InSphero 3D InSight™ Human Liver Disease Microtissue models to evaluate praliciguat, a systemic small molecule stimulator of soluble guanylate cyclase (sGC), as a potential treatment for non-alcoholic steatohepatitis (NASH) and fibrotic liver disease. Study results support further investigation of sGC stimulation as a potential therapeutic approach for NASH and fibrosis, and validate the utility of 3D InSight™ human liver disease models for preclinical drug screening.

Read More
 
 
Jul 17, 2019

July 17, 2019 – InSphero launches industry’s first automation-compatible 3D human liver disease platform for NASH drug discovery and screening

InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver (steatosis) to inflammation (NASH) and scarring (fibrosis) of the liver. This game-changing preclinical discovery platform enables scalable in vitro drug efficacy assessment, screening, combinatorial testing as well as the study of complex NASH pathophysiology.

Read More
 
 
Jun 19, 2019

June 19, 2019 – New Study Highlights Value of Physiologically Relevant 3D InSight™ Liver Microtissues for Nanomaterial Safety Assessments

Findings represent key milestone in PATROLS initiative to establish tools for evaluating health and environmental risks of nanomaterials

Read More
 
 
Feb 12, 2019

February 13, 2019 – InSphero Appoints Distinguished Pharma Industry Executive Prof. Armin Wolf as Chief Scientific Officer

With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D

Read More
 
 
Jan 31, 2019

January 31, 2019 – InSphero Organ-on-a-Chip Solutions Featured in SLAS Technology

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based multi-organ models.

Read More
 
 
Jan 24, 2019

January 24, 2019 – Registration Open for 2019 New Frontiers in 3D Conference

Exclusive one-day scientific meeting to discuss practical applications of innovative 3D-cell and organ-on-a-chip technologies to be held April 25, 2019, in Cambridge, MA

Read More
 
 
Dec 19, 2018

December 19, 2018 – InSphero and Path BioAnalytics Announce Partnership to Develop Advanced 3D Airway Tissue Model for Cystic Fibrosis Research

Path BioAnalytics will employ InSphero 3D cell technology to produce organoids from primary cystic fibrosis patient tissues to aid in development of new treatments.

Read More
 
 
Nov 29, 2018

November 29, 2018 – AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study

AstraZeneca Relies on 3D InSight™ Human Islet Microtissues in Pancreatic Beta-cell Study InSphero human islet model helps reveal effects of gene silencing on pancreatic cell function using novel antisense oligonucleotide […]

Read More
 
 
Oct 11, 2018

October 11, 2018 – InSphero achieves new milestone with Akura™ Flow organ-on-a-chip technology in low-clearance drug study

Government research project to predict hepatic clearance of drugs in humans using Akura™ Flow system results in development partnerships with top pharma companies.

Read More
 
 
Jun 13, 2018

June 13, 2018 – InSphero Receives Additional USD 10m for Organ-on-a-Chip Disease Models

Comprehensive, customizable platforms for preclinical drug safety and efficacy testing, coupled with emerging organ-on-a-chip technology, garner investor support

Read More
 
 
Jun 11, 2018

June 11, 2018 – InSphero Partners with ALPCO to Advance Diabetes Research

InSphero extends 3D InSight™ Diabetes Discovery Platform to include ALPCO STELLUX® Chemiluminescent ELISA technology for assessment of pancreatic β-cell function.

Read More
 
 
Feb 08, 2018

February 8, 2018 – InSphero Introduces Akura™ Flow Microphysiological System at SLAS2018

Global leader in 3D cell culture technology to deliver standardized 3D models in advanced microfluidic format ideal for organ on a chip applications.

Read More
 
 
Feb 01, 2018

February 1, 2018 – InSphero Joins Global Consortium Dedicated to Enhancing Safety Testing of Engineered Nanomaterials

Nanosafety experts from more than 30 institutions convene in Swansea, Wales, for PATROLS project kick off meeting.

Read More
 
 
Jan 03, 2018

January 3, 2018 – InSphero Certified for ISO 9001:2015

InSphero demonstrates commitment to customer satisfaction, superior quality, and continuous improvement by adhering to new ISO 9001:2015 standards.

Read More
 
 
Oct 26, 2017

October 26, 2017 – InSphero and Charles River Announce PDX Partnership

Charles River to license PDX lines to InSphero for development of 3D InSight™ PDX Microtissues, expansion of in vitro oncology services.

Read More
 
 
Oct 18, 2017

October 18, 2017 – InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC New 3D InSight™ Human Liver Fibrosis Model represents a powerful tool for screening efficacy […]

Read More
 
 
Jun 29, 2017

June 29, 2017 – Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury

Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury Archives of Toxicology publication reveals microtissues are twice as sensitive as […]

Read More
 
 
Jun 19, 2017

June 19, 2017 – ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening

ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening ETH Zurich researchers present single-islet study using novel microfluidic setup to display in vivo-like temporal insulin […]

Read More
 
 
May 03, 2017

May 03, 2017 – InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS) Joint study will accelerate development of physiologically relevant 3D models for anti-cancer drug screening. PDF Version   Schlieren, […]

Read More
 
 
Apr 27, 2017

April 27, 2017 – InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury Research effort will use InSphero 3D InSight™ Human Liver Microtissues to develop novel assays to predict […]

Read More
 
 
Apr 18, 2017

April 18, 2017 – NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017 Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective […]

Read More
 
 
Apr 03, 2017

April 03, 2017 – Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies

Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies InSphero presents latest data demonstrating immune cell interaction with 3D tumor models for in vitro efficacy testing of oncology drugs and […]

Read More
 
 
Mar 27, 2017

March 27, 2017 – InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing

InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing Customer and company presentations highlight InSphero 3D InSight™ Liver Microtissues as [...]

Read More
 
 
Mar 16, 2017

March 16, 2017 – InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting 3D liver microtissues comprised of cynomolgus hepatocytes provide physiologically relevant in vitro model for investigating species-specific liver […]

Read More